Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have earned an average rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $20.2857.

Several equities analysts have recently commented on ENTA shares. Rodman & Renshaw began coverage on Enanta Pharmaceuticals in a report on Thursday, March 26th. They set a “buy” rating and a $20.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday, June 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Monday, April 20th. Finally, Wall Street Zen lowered Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, May 31st.

Enanta Pharmaceuticals Stock Performance

Shares of NASDAQ ENTA traded down $0.55 during midday trading on Friday, hitting $13.70. The company’s stock had a trading volume of 179,224 shares, compared to its average volume of 245,746. Enanta Pharmaceuticals has a 1-year low of $6.43 and a 1-year high of $17.15. The firm’s fifty day moving average price is $13.46 and its 200-day moving average price is $13.64. The firm has a market cap of $398.40 million, a P/E ratio of -5.29 and a beta of 0.96.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.01. Enanta Pharmaceuticals had a negative net margin of 89.56% and a negative return on equity of 64.04%. The firm had revenue of $17.16 million for the quarter, compared to analyst estimates of $17.03 million. As a group, research analysts predict that Enanta Pharmaceuticals will post -1.79 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC increased its holdings in shares of Enanta Pharmaceuticals by 91.6% in the 4th quarter. Janus Henderson Group PLC now owns 3,729,659 shares of the biotechnology company’s stock worth $58,761,000 after acquiring an additional 1,782,745 shares during the period. Commodore Capital LP acquired a new position in Enanta Pharmaceuticals during the 3rd quarter valued at about $9,576,000. Krensavage Asset Management LLC grew its position in Enanta Pharmaceuticals by 30.8% in the 4th quarter. Krensavage Asset Management LLC now owns 2,766,390 shares of the biotechnology company’s stock worth $43,626,000 after purchasing an additional 651,946 shares during the last quarter. Farallon Capital Management LLC grew its position in Enanta Pharmaceuticals by 30.6% in the 4th quarter. Farallon Capital Management LLC now owns 2,772,262 shares of the biotechnology company’s stock worth $43,719,000 after purchasing an additional 650,000 shares during the last quarter. Finally, Spruce Street Capital LP increased its stake in shares of Enanta Pharmaceuticals by 139.3% in the first quarter. Spruce Street Capital LP now owns 932,598 shares of the biotechnology company’s stock valued at $11,779,000 after purchasing an additional 542,911 shares during the period. Institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.